The Harry Glorikian Show
Harry Glorikian
All episodes
Best episodes
Top 10 The Harry Glorikian Show Episodes
Goodpods has curated a list of the 10 best The Harry Glorikian Show episodes, ranked by the number of listens and likes each episode have garnered from our listeners. If you are listening to The Harry Glorikian Show for the first time, there's no better place to start than with one of these standout episodes. If you are a fan of the show, vote for your favorite The Harry Glorikian Show episode by adding your comments to the episode page.
Modicus Prime Safeguards Drug Manufacturing
The Harry Glorikian Show
11/21/23 • 44 min
Quality control is one of those things that only a select few people pay attention to—until something goes wrong, then everyone cares. That's especially true in the drug manufacturing industry, where episodes like cross-contamination in a drug factory can shut down a production line and create instant shortages of important medicines. And if a contaminated medicines ever does get shipped out to clinics or stores, people’s lives can be at stake. So drug makers are usually pretty receptive toward any new technology that can help them detect manufacturing problems before they get out of hand.
That’s the market opening that Harry's guest Taylor Chartier says she saw back in 2020, during the coronavirus pandemic. Chartier watched the stories about the Baltimore company Emergent BioSolutions, which was manufacturing vaccines for Johnson & Johnson and AstraZeneca and had to throw out millions of doses of both vaccines due to suspected cross-contamination, and thought: there has to be a better way. So she started her own company. And today her startup Modicus Prime is partnering with top pharma companies to use new machine vision and AI capabilities to catch drug manufacturing problems faster.
For a full transcript of this episode, please visit our episode page at http://www.glorikian.com/podcast
Please rate and review The Harry Glorikian Show on Apple Podcasts! Here's how to do that from an iPhone, iPad, or iPod touch:
1. Open the Podcasts app on your iPhone, iPad, or Mac.
2. Navigate to The Harry Glorikian Show podcast. You can find it by searching for it or selecting it from your library. Just note that you'll have to go to the series page which shows all the episodes, not just the page for a single episode.
3. Scroll down to find the subhead titled "Ratings & Reviews."
4. Under one of the highlighted reviews, select "Write a Review."
5. Next, select a star rating at the top — you have the option of choosing between one and five stars.
6. Using the text box at the top, write a title for your review. Then, in the lower text box, write your review. Your review can be up to 300 words long.
7. Once you've finished, select "Send" or "Save" in the top-right corner.
8. If you've never left a podcast review before, enter a nickname. Your nickname will be displayed next to any reviews you leave from here on out.
9. After selecting a nickname, tap OK. Your review may not be immediately visible.
That's it! Thanks so much.
Christine Lemke on Evidation's Push to Use Wearables in Healthcare
The Harry Glorikian Show
01/04/21 • 38 min
This week Harry catches up with Christine Lemke from Evidation Health, a startup in San Mateo, CA, that helps drug developers and other organizations analyze the effectiveness of smart devices and wearables in new types of therapies. Lemke is Evidation's co-CEO.
Our Fitbits and Apple Watches are with us so much of the time that the data they collect can go way beyond telling us whether we’ve completed our 10,000 steps for the day. They can also help doctors diagnose cardiovascular problems, and even provide early signs of cognitive changes like the onset of dementia. But the data comes in so many forms from so many sources that it’s a real chore to set up population-wide studies and keep the incoming data organized and anonymized. That’s Evidation's specialty.
The company came together in its current form when a company Lemke helped to start, The Activity Exchange, merged with another company called Evidation. (Harry helped to incubate Evidation at GE Ventures with colleagues Rowan Chapman and Deborah Kilpatrick.) In its early years, Evidation focused simply on helping other companies prove that real-life data from consumer wearables was reliable enough to be useful in health decisions. But nowadays Evidation works mostly with Big Tech and Big Pharma companies like Eli Lilly, Johnson & Johnson, and Apple to test specific ideas, like whether data from people’s smart watches and smart phones can help predict cardiovascular disease or cognitive decline early enough to help slow or reverse the conditions with new drugs.
In July 2020 Evidation raised $45 million in Series D funding to expand its so-called Achievement platform, which includes a network of nearly 4 million people who’ve agreed to share at-home sensor data and other health records. In September Lemke became co-CEO alongside Deb Kilpatrick. Before joining Evidation, she was co-founder and COO of Sense Networks, a machine learning platform for mobile activity data. And before that she worked at Microsoft, helping to manage the Xbox hardware engineering group.
You can find more details about this episode, as well as the entire run of MoneyBall Medicine's 50+ episodes, at https://glorikian.com/moneyball-medicine-podcast/
Please rate and review The Harry Glorikian Show on Apple Podcasts! Here's how to do that from an iPhone, iPad, or iPod touch:
1. Open the Podcasts app on your iPhone, iPad, or Mac.
2. Navigate to The Harry Glorikian Show podcast. You can find it by searching for it or selecting it from your library. Just note that you'll have to go to the series page which shows all the episodes, not just the page for a single episode.
3. Scroll down to find the subhead titled "Ratings & Reviews."
4. Under one of the highlighted reviews, select "Write a Review."
5. Next, select a star rating at the top — you have the option of choosing between one and five stars.
6. Using the text box at the top, write a title for your review. Then, in the lower text box, write your review. Your review can be up to 300 words long.
7. Once you've finished, select "Send" or "Save" in the top-right corner.
8. If you've never left a podcast review before, enter a nickname. Your nickname will be displayed next to any reviews you leave from here on out.
9. After selecting a nickname, tap OK. Your review may not be immediately visible.
That's it! Thanks so much.
Rayid Ghani Explains How AI Can Both Predict and Shape Patient Behavior
The Harry Glorikian Show
08/20/20 • 44 min
In this week's show Harry interviews Rayid Ghani, a computer scientist at Carnegie Mellon University who studies how to use AI and data science to model and influence people's behavior in realms like politics, healthcare, education, and criminal justice.
Ghani tell Harry he grew up hating coding, since the very need for it showed that "computers are really stupid and dumb." But Ghani says he eventually realized that machine learning can change that by allowing programmers to teach computers the rules of the game, at which point they can improve on their own and learn to solve real problems.
Ghani went on to become chief data scientist for the 2012 Obama campaign, and he has since used what he learned about data analytics to study applications of AI to large-scale social problems in many areas, including healthcare. He's currently Distinguished Career Professor in the Machine Learning Department at Carnegie Mellon University's School of Computer Science.
In political campaigns, Ghani says, machine learning and other forms of AI are used not just to predict voter behavior but, in combination with behavioral psychology insights, to change it. "Why not do the same thing for issues with effects that are much, much broader?" he asks. "In health, we do fairly macro policies around 'everybody should get this vaccine.' But often you don't have enough resources to make sure that happens." AI and machine learning may be able to help by predicting who needs help the most, and then persuading them to make the necessary changes—for example, changing their diet and lifestyle to avoid Type 2 diabetes. But it's all a tricky area to study, he says. "Those are the two things we need to couple together—prediction combined with behavior change—and that requires both the data about these individuals and, more importantly, creates ethical issues about how we test these ideas."
Please rate and review The Harry Glorikian Show on Apple Podcasts! Here's how to do that from an iPhone, iPad, or iPod touch:
1. Open the Podcasts app on your iPhone, iPad, or Mac.
2. Navigate to The Harry Glorikian Show podcast. You can find it by searching for it or selecting it from your library. Just note that you'll have to go to the series page which shows all the episodes, not just the page for a single episode.
3. Scroll down to find the subhead titled "Ratings & Reviews."
4. Under one of the highlighted reviews, select "Write a Review."
5. Next, select a star rating at the top — you have the option of choosing between one and five stars.
6. Using the text box at the top, write a title for your review. Then, in the lower text box, write your review. Your review can be up to 300 words long.
7. Once you've finished, select "Send" or "Save" in the top-right corner.
8. If you've never left a podcast review before, enter a nickname. Your nickname will be displayed next to any reviews you leave from here on out.
9. After selecting a nickname, tap OK. Your review may not be immediately visible.
That's it! Thanks so much.
How Matthew Might Is Using Computation to Fight Rare Diseases
The Harry Glorikian Show
09/14/21 • 48 min
Harry's guest this week is Matthew Might, director of the Hugh Kaul Precision Medicine Institute at the University of Alabama at Birmingham. Might trained as a computer scientist, but a personal odyssey inspired him to make the switch into precision medicine. Now he uses computational tools such as knowledge graphs and natural language processing to find existing drug compounds that might help cure people with rare genetic disorders.
Might's odyssey began with the birth of his first child, Bertrand, in 2007. Bertrand seemed healthy at first, but soon developed a cluster of symptoms including developmental delay, lack of motor control, inability to produce tears, and epilepsy-like seizures. For more than four years, doctors were unable to diagnose Bertrand's condition. But eventually a technique called whole exome sequencing revealed that he had no functioning gene for NGLY1, an enzyme that normally removes sugars from misfolded proteins. Bertrand, it turned out, was the first person in the world to be diagnosed with NGLY1 deficiency—and as with so many other "N of 1" diseases, there was no known treatment.
After the diagnosis, Matthew and and his wife Cristina decided to used social media and the Internet to locate other patients with NGLY1 disorders around the world. Eventually the couple discovered 70 patients with the condition. Reasoning from first principles about the role of NGLY1, Might discovered that giving Bertrand a sugar called N-acetylglucosamine, a metabolite of NGLY1, helped restore his ability to form tears. (Around the same time Might, co-founded a startup that screened existing drugs to see whether they could treat ion-channel-driven epilepsy similar to what Bertrand experienced; the company was quickly sold to Q State Biosciences.)
Working with collaborators at the University of Utah, Might studied planarian worms that had been engineered to lack NGLY1, and found that those that also lacked a second gene had a higher survival rate. That meant one way to treat Bertrand might be to inhibit the analogous gene in humans, in this case a gene for an enzyme called ENGase. Might used computational screening to look for existing drugs that would be inverse in shape and charge to the catalytic domain on ENGase, and might therefore inhibit it.
He found more than a dozen drugs that were already FDA-approved. One was Prevacid, a proton-pump inhibitor sold as common over-the-counter medication for acid reflux. It turned out that as a previously unsuspected side effect, Prevacid is an ENGase inhibitor. Bertrand started taking the drug, and Might says it was one of the treatments that helped to extend and enrich his life.
Sadly, Bertrand died in 2020 at the age of 12. But by that point, his father’s work to apply computation to basic biology, and thereby speed up the treatment of rare disorders, had sparked a movement that will long outlive him. Years before, Bertrand's story had caught the attention of the Obama administration, which invited Matthew to the White House to work on a range of precision-medicine projects. One was an NIH program called the All of Us initiative, which is collecting the genomes and medical records of a million Americans to search for correlations between mutations and health impacts. Might also launched a smaller pilot program called the Patient Empowered Precision Medicine Alliance (PEPMA) with the goal of repeating what he and Cristina had done for NGLY1 deficiency—that is, quickly diagnose the problem and identify possible treatments.
Might resigned from his White House role about one year into the Trump administration, then got an offer from University of Alabama to come to Birmingham to set up an institute to scale up the PEPMA idea. One project there called mediKanren involves using logic programming to highlight what Might calls the "unknown knowns" in the medical literature and identify existing, approved drugs that might treat rare disorders.
Please rate and review MoneyBall Medicine on Apple Podcasts! Here's how to do that from an iPhone, iPad, or iPod touch:
1. Open the Podcasts app on your iPhone, iPad, or Mac.
2. Navigate to the page of the MoneyBall Medicine podcast. You can find it by searching for it or selecting it from your library. Just note that you'll have to go to the series page which shows all the episodes, not just the page for a single episode.
3.Scroll down to find the subhead titled "Ratings & Reviews."
4.Under one of the highlighted reviews, select "Write a Review."
5.Next, select a star rating at the top — you have the option of choosing between one and five stars.
6.Using the text box at the top, write a title for your review. Then, in the lower text box, write your review. Your review can be up to 300 words long.
7.
Why AI-based Computational Pathology Detects More Cancers
The Harry Glorikian Show
11/09/21 • 49 min
Chances are you or someone you love has had a biopsy to check for cancer. Doctors got a tissue sample and they sent it into a pathology lab, and at some point you got a result back. If you were lucky, it was negative and there was no cancer. But have you ever wondered exactly what happens in between those steps? Until recently, it’s been a meticulous but imperfect manual process where a pathologist would put a thin slice of tissue under a high-powered microscope and examine the cells by eye, looking for patterns that indicate malignancy. But now the process is going digital—and growing more accurate.
Harry's guest this week is Leo Grady, CEO of, Paige AI, which makes an AI-driven test called Paige Prostate. Grady says that in a clinical study, pathologists who had help from the Paige system accurately diagnosed prostate cancer almost 97 percent of the time, up from 90 percent without the tool. That translates into a 70 percent reduction in false negatives—nice odds if your own health is on the line. This week on the show, Grady explains explain how the Paige test works, how the company trained its software to be more accurate than a human pathologist, how it won FDA approval for the test, and what it could all mean for the future of cancer diagnosis and treatment.
Please rate and review The Harry Glorikian Show on Apple Podcasts! Here's how to do that from an iPhone, iPad, or iPod touch:
1. Open the Podcasts app on your iPhone, iPad, or Mac.
2. Navigate to The Harry Glorikian Show podcast. You can find it by searching for it or selecting it from your library. Just note that you'll have to go to the series page which shows all the episodes, not just the page for a single episode.
3. Scroll down to find the subhead titled "Ratings & Reviews."
4. Under one of the highlighted reviews, select "Write a Review."
5. Next, select a star rating at the top — you have the option of choosing between one and five stars.
6. Using the text box at the top, write a title for your review. Then, in the lower text box, write your review. Your review can be up to 300 words long.
7. Once you've finished, select "Send" or "Save" in the top-right corner.
8. If you've never left a podcast review before, enter a nickname. Your nickname will be displayed next to any reviews you leave from here on out.
9. After selecting a nickname, tap OK. Your review may not be immediately visible.
That's it! Thanks so much.
Full Transcript
Harry Glorikian: Hello. I’m Harry Glorikian. Welcome to The Harry Glorikian Show, the interview podcast that explores how technology is changing everything we know about healthcare.
Artificial intelligence. Big data. Predictive analytics. In fields like these, breakthroughs are happening way faster than most people realize.
If you want to be proactive about your own health and the health of your loved ones, you’ll need to learn everything you can about how medicine is changing and how you can take advantage of all the new options.
Explaining this approaching world is the mission of my new book, The Future You. And it’s also our theme here on the show, where we bring you conversations with the innovators, caregivers, and patient advocates who are transforming the healthcare system and working to push it in positive directions.
Chances are you or someone you love has had a biopsy to check for cancer.
Doctors got a tissue sample and they sent it into a pathology lab, and at some point you got a result back. If you were lucky it was negative and there was no cancer.
But have you ever wondered exactly what happens in between those steps?
Well, until recently, it’s been an extremely meticulous manual process.
A pathologist would create a very thin slice of your tissue, put it under a high-powered microscope, and examine the cells by eye, looking for patterns that indicate malignancy.
But recently the process has started to go digital.
For one thing, the technology to make a digital scan of a pathology slide has been getting cheaper. That’s a no-brainer, since it makes it way easier for a pathologist to share an image if they want a second opinion.
But once the data is available digitally, it opens up a bunch of additional possibilities.
Including letting computers try their hand at pathology.
That’s what’s happening at a company called Paige AI, which makes a newly FDA-approved test for prostate cancer called Paige Prostate.
The test uses computer vision and machine learning to find spots on prostate biopsy slides that look suspicious, so a human pathologist can take a closer look.
So why should you care?
...Finally, a Drug Company Listens to People with Hearing Loss
The Harry Glorikian Show
03/29/22 • 57 min
In a day and age when it feels like there are drugs for everything—from restless legs to toenail fungus to stage fright—it's strange the drug industry has almost completely ignored one of our most important organs: our ears. Given that 15 percent of people in the U.S. report at least some level of hearing loss, you’d think drug makers would be doing more to figure out how they can help. Well, now there’s at least one company that is. Cambridge, Massachusetts-based Decibel Therapeutics went public in 2021 to help raise money to fund its research on ways to treat a specific form of deafness caused by a rare genetic mutation. Decibel is testing a gene therapy that would be administered only to cells in the inner ear and would provide patients with a correct, working copy of the otoferlin gene, which is inactive in about 10 percent of kids born with auditory neuropathy. Harry's guest this week is Decibel’s CEO Laurence Reid, who explains how the company’s research is going, and how Decibel hopes to make up for all those decades when the pharmaceutical business had basically zero help to offer for people with hearing loss.
Please rate and review The Harry Glorikian Show on Apple Podcasts! Here's how to do that from an iPhone, iPad, or iPod touch:
1. Open the Podcasts app on your iPhone, iPad, or Mac.
2. Navigate to The Harry Glorikian Show podcast. You can find it by searching for it or selecting it from your library. Just note that you'll have to go to the series page which shows all the episodes, not just the page for a single episode.
3. Scroll down to find the subhead titled "Ratings & Reviews."
4. Under one of the highlighted reviews, select "Write a Review."
5. Next, select a star rating at the top — you have the option of choosing between one and five stars.
6. Using the text box at the top, write a title for your review. Then, in the lower text box, write your review. Your review can be up to 300 words long.
7. Once you've finished, select "Send" or "Save" in the top-right corner.
8. If you've never left a podcast review before, enter a nickname. Your nickname will be displayed next to any reviews you leave from here on out.
9. After selecting a nickname, tap OK. Your review may not be immediately visible.
That's it! Thanks so much.
Transcript
Harry Glorikian: Hello. I’m Harry Glorikian, and this is The Harry Glorikian Show, where we explore how technology is changing everything we know about healthcare.
These days, it feels like there’s a medicine for almost everything.
There are drugs to calm your restless legs. There are drugs to treat fungal infections under your toenails or fingernails. There are even drugs to calm down performers who suffer from stage fright.
So it feels odd that the drug industry has almost completely ignored one of our most important organs: our ears.
15 percent of people in the U.S. report at least some level of hearing loss, so you’d think drug makers would be doing more to figure out how they can help.
Well, now there’s at least one company that is.
It’s a six-year-old company based in Cambridge, Massachusetts called Decibel Therapeutics.
Decibel went public in 2021 to help raise money to fund its research on ways to treat a specific form of deafness caused by a rare genetic mutation.
It turns out that in about 10 percent of children who are born with auditory neuropathy, the problem is a mutation in the gene for a protein called otoferlin.
It’s involved in the formation of tiny bubbles or vesicles that carry neurotransmitters across the synapses between the inner hair cells that pick up sound and auditory neurons in the brain.
Decibel is testing a gene therapy that would be administered only to cells in the inner ear and would provide patients with a correct, working copy of the otoferlin gene.
Otoferlin wasn’t even discovered until 1999. So the fact that there’s a drug company working to correct mutations in the gene for the protein is a great example of how genomics is enabling big advances in medicine.
My guest today is Decibel’s CEO Laurence Reid.
And in our conversation he explained how the company’s work is coming along, and how Decibel hopes to make up for all those decades when the pharmaceutical business had basically zero help to offer for people with hearing loss.
Harry Glorikian: Laurence, welcome to the show. It's great to have you here.
Laurence Reid: Yeah. Hey, good morning, Harry. Great to see you again. Thank you. Thanks very much for the opportunity to join you. I'm looking forward to it.
Harry Glorikian: Yeah,...
At Univfy, Mylene Yao Is Making IVF More Predictable and Affordable
The Harry Glorikian Show
11/22/22 • 56 min
About half a million babies are born every year through IVF. That number would probably be a lot higher if the procedure were cheaper and more accessible—but making that happen would mean transforming IVF from an artisanal craft into something more like a modern automated factory, with AI helping doctors and technicians make faster and better decisions at every step.
And that’s exactly what Harry's guest Mylene Yao, the co-founder of Univfy, is doing. Univfy helps patients with two aspects of the IVF process. The first is using machine learning to provide patients with a more accurate assessment of the odds of success, before they decide whether to invest in one or more IVF cycles, which can cost up to $30,000 per cycle. The second is financing. Univfy works with a bank called Lightstream to provide up to $100,000 in financing for up to three rounds of IVF, with a large refund as part of the deal if the treatments don’t result in a baby.
Harry talks with Dr. Yao about the prospects for far broader access to IVF, now that the field is finally adopting more ideas from the worlds of technology and finance.
For a full transcript of this episode, please visit our episode page at http://www.glorikian.com/podcast
Please rate and review The Harry Glorikian Show on Apple Podcasts! Here's how to do that from an iPhone, iPad, or iPod touch:
1. Open the Podcasts app on your iPhone, iPad, or Mac.
2. Navigate to The Harry Glorikian Show podcast. You can find it by searching for it or selecting it from your library. Just note that you'll have to go to the series page which shows all the episodes, not just the page for a single episode.
3. Scroll down to find the subhead titled "Ratings & Reviews."
4. Under one of the highlighted reviews, select "Write a Review."
5. Next, select a star rating at the top — you have the option of choosing between one and five stars.
6. Using the text box at the top, write a title for your review. Then, in the lower text box, write your review. Your review can be up to 300 words long.
7. Once you've finished, select "Send" or "Save" in the top-right corner.
8. If you've never left a podcast review before, enter a nickname. Your nickname will be displayed next to any reviews you leave from here on out.
9. After selecting a nickname, tap OK. Your review may not be immediately visible.
That's it! Thanks so much.
Niven Narain and How AI and Machine Learning Are Changing Drug Discovery
The Harry Glorikian Show
09/15/18 • 39 min
Harry interviews Niven Narain, the co-founder, president and CEO of Berg, a Boston-based biopharma company driving the next generation of drugs and diagnostics by combining patient-driven biology and AI to unravel actionable disease insight. Narain has overseen development of Berg’s clinical stage assets and pipeline and forged strategic partnerships with industry academic and US and UK governments. He says Berg's philosophy is to combine a systems biology architecture with patients' demographic data and clinical outcome data, and then apply Bayesian artificial intelligence algorithms to drive better understanding of diseases.
To learn more visit glorikian.com/podcast/
Please rate and review The Harry Glorikian Show on Apple Podcasts! Here's how to do that from an iPhone, iPad, or iPod touch:
1. Open the Podcasts app on your iPhone, iPad, or Mac.
2. Navigate to The Harry Glorikian Show podcast. You can find it by searching for it or selecting it from your library. Just note that you'll have to go to the series page which shows all the episodes, not just the page for a single episode.
3. Scroll down to find the subhead titled "Ratings & Reviews."
4. Under one of the highlighted reviews, select "Write a Review."
5. Next, select a star rating at the top — you have the option of choosing between one and five stars.
6. Using the text box at the top, write a title for your review. Then, in the lower text box, write your review. Your review can be up to 300 words long.
7. Once you've finished, select "Send" or "Save" in the top-right corner.
8. If you've never left a podcast review before, enter a nickname. Your nickname will be displayed next to any reviews you leave from here on out.
9. After selecting a nickname, tap OK. Your review may not be immediately visible.
That's it! Thanks so much.
Transcript
Harry Glorikian: Welcome to the Moneyball medicine podcast I'm your host Harry Glorikian. This series is all about the data-driven transformation of the healthcare and life sciences landscape. Each episode we dive deep through one-on-one interviews with leaders in the new cost-conscious value-based healthcare economy. We look at the challenges and opportunities they're facing and their predictions for the years to come.
Okay welcome to another edition of Moneyball Medicine. Today I have Niven Narayan who is co-founder president and CEO of Berg, a Boston-based biopharma company driving the next generation of drugs and Diagnostics by combining patient driven biology and artificial intelligence to unravel actionable disease insight. He has overseen development of Berg's clinical stage assets and pipeline and forged strategic partners with industry academia and US and UK government's.
Niven is most passionate about improving patient care and enabling increased access to innovative medicines to improve healthcare outcomes.
Niven welcome to Moneyball Medicine podcast, it's great to spend time together again.
Niven Narain: It’s great to be on again, Harry, it's always good to catch up and I think it's such an important continuous dialogue you know given how quickly technology is moving in healthcare. So, again happy to be on.
Harry Glorikian: I had the pleasure of learning about Berg and coming in and taking a look at your systems and being brought up to speed, on what you guys are doing during the writing of Moneyball Medicine. But since then you know and maybe for the people listening for the first time and who don't know the company. Can you tell me a little bit about you know this whole concept that you have of a artificial-intelligence, drug discovery model engine and where we were back what two plus years ago and where you are now?
Niven Narain: Yes, sure you know, so the company was really founded on this the philosophy that we should at this point in developed and this is about ten years back. We took a good hard look of how could we use biology in a more fundamental sense to drive a greater understanding of diseases. But importantly how our disease is different than a healthy, an otherwise healthy individual or a healthy cell or a healthy tissue. And the approach that we took at that time was really to combine a systems biology architecture with a combination of a patient's demographic data, their clinical outcome data.
And then we wanted to look at a nove...
John Glaser and How AI is Affecting Electronic Medical Records Systems
The Harry Glorikian Show
10/26/18 • 34 min
Harry's guest John Glaser, senior vice president of Population Health at Cerner, speculates on how business models in healthcare are changing and how artificial intelligence and EMR systems will work together in the future.
Please rate and review The Harry Glorikian Show on Apple Podcasts! Here's how to do that from an iPhone, iPad, or iPod touch:
1. Open the Podcasts app on your iPhone, iPad, or Mac.
2. Navigate to The Harry Glorikian Show podcast. You can find it by searching for it or selecting it from your library. Just note that you'll have to go to the series page which shows all the episodes, not just the page for a single episode.
3. Scroll down to find the subhead titled "Ratings & Reviews."
4. Under one of the highlighted reviews, select "Write a Review."
5. Next, select a star rating at the top — you have the option of choosing between one and five stars.
6. Using the text box at the top, write a title for your review. Then, in the lower text box, write your review. Your review can be up to 300 words long.
7. Once you've finished, select "Send" or "Save" in the top-right corner.
8. If you've never left a podcast review before, enter a nickname. Your nickname will be displayed next to any reviews you leave from here on out.
9. After selecting a nickname, tap OK. Your review may not be immediately visible.
That's it! Thanks so much.
Transcript
Harry Glorikian: Welcome to the Money ball medicine podcast. I'm your host Harry Glorikian, this series is all about the data-driven transformation of the healthcare and life sciences landscape. Each episode we dive deep through one-on-one interviews with leaders in the new cost-conscious, value-based healthcare economy. We look at the challenges and opportunities they're facing and their predictions for the years to come.
My guest today is John Glaser, who is the senior vice president of Population Health at Cerner. Cerner is a health IT company that is one of the largest suppliers of electronic health record systems in the United States. John joined Cerner in 2015 as part of the Siemens health services acquisition, where he was the chief executive officer. Prior to Siemens, John was vice president and chief information officer at Partners HealthCare. He also previously served as vice president of information systems at Brigham and Women's Hospital.
John received his PhD from the University of Minnesota, he has written over 200 articles and three books on the strategic application of IT and health care. Including the most widely used textbook on the topic, “Healthcare information systems a practical approach for health care”. John is on the faculty of the Wharton School at the University of Pennsylvania, the medical university of Southern Carolina, the School of biomedical informatics at the Texas Health Science Center and the Harvard School of Public Health.
John focuses on strategic relationships with Cerner clients and advancing Cerner's population health solutions and services. John, welcome to Moneyball medicine, it's great to have you here.
John Glaser: Harry, it's a pleasure.
Harry Glorikian: John, tell me what does it mean to be vice president of Population Health. What is Population Health?
John Glaser: Well, it's a fuzzy term in some ways but basically the idea is that there are organizations. They'd say I'm accountable for the health care and the health of a group of people, it might be an employer who says I'm responsible for my employees or the state Department or a health care provider, who has a series of lives attributed to the - health plan, but the point is they're accountable. And so they need a series of tools and technologies that help them manage health and manage health care this is analytics to see you know who's receiving what care, how costly is it.
This is a series of care management to the degree they need someone to help them navigate the care process or social determinants. So anyway, at the end of the day accountable organizations need technology to help them fulfill their obligations to those who they are to serve, and that's what population health IT staff intends to do.
Harry Glorikian: You know medicine has been historically based on a fee-for-service model, where you're paid on what you do. And now that we've seen sort of a shift not as much as I'd like to see, but a shift towards value-based medicine, in other word...
Handheld Ultrasound by Butterfly Network: Faster, Cheaper, Better
The Harry Glorikian Show
08/15/23 • 53 min
Harry's guest this week is Joe DeVivo, the new CEO of Butterfly Network. The company's goal is to make it radically easier for doctors or medical technicians to perform an ultrasound exam on any part of the body, and radically cheaper for a patient to get one. The companyt makes an FDA-cleared, handheld ultrasound scanner called the Butterfly iQ. The first big thing that’s different about the iQ is that it uses silicon-based microelectromechanical sensors, instead of a traditional piezoelectric crystal element, to generate and receive the ultrasound waves. That means the device is fully digital, rather than analog. The second big thing that’s different is that the iQ transmits the ultrasound data to a standard iPhone or iPad instead of a big, expensive ultrasound cart. The doctor or technician can see the live ultrasound image right on a handheld device, and use the image to aim the sensor correctly to get the best possible picture to make a diagnosis. All of that is bringing down the cost of equipping a clinic with ultrasound technology dramatically, and over time it should also bring down the cost of administering an ultrasound exam. It also opens up the possibility of adding AI assistance to the software, so that doctors or technicians can get usable images with less training. The net result is that Butterfly is making it economically feasible to use ultrasound for diagnostic imaging in a lot more places, including clinics in developing countries where ultrasound was out of reach before due to the high cost of the technology and a shortage of trained ultrasonographers.
For a full transcript of this episode, please visit our episode page at http://www.glorikian.com/podcast
Please rate and review The Harry Glorikian Show on Apple Podcasts! Here's how to do that from an iPhone, iPad, or iPod touch:
1. Open the Podcasts app on your iPhone, iPad, or Mac.
2. Navigate to The Harry Glorikian Show podcast. You can find it by searching for it or selecting it from your library. Just note that you'll have to go to the series page which shows all the episodes, not just the page for a single episode.
3. Scroll down to find the subhead titled "Ratings & Reviews."
4. Under one of the highlighted reviews, select "Write a Review."
5. Next, select a star rating at the top — you have the option of choosing between one and five stars.
6. Using the text box at the top, write a title for your review. Then, in the lower text box, write your review. Your review can be up to 300 words long.
7. Once you've finished, select "Send" or "Save" in the top-right corner.
8. If you've never left a podcast review before, enter a nickname. Your nickname will be displayed next to any reviews you leave from here on out.
9. After selecting a nickname, tap OK. Your review may not be immediately visible.
That's it! Thanks so much.
Show more best episodes
Show more best episodes
FAQ
How many episodes does The Harry Glorikian Show have?
The Harry Glorikian Show currently has 135 episodes available.
What topics does The Harry Glorikian Show cover?
The podcast is about Life Sciences, Health & Fitness, Analytics, Data, Medicine, Podcasts, Big Data, Technology, Artificial Intelligence, Machine Learning and Healthcare.
What is the most popular episode on The Harry Glorikian Show?
The episode title 'Richard Fox: Scaling Genome Editing To Drive The Industrial Bio-Economy' is the most popular.
What is the average episode length on The Harry Glorikian Show?
The average episode length on The Harry Glorikian Show is 47 minutes.
How often are episodes of The Harry Glorikian Show released?
Episodes of The Harry Glorikian Show are typically released every 14 days.
When was the first episode of The Harry Glorikian Show?
The first episode of The Harry Glorikian Show was released on Sep 11, 2018.
Show more FAQ
Show more FAQ